CD274 and glioblastoma: The first extensive evaluation of PD-1/PD-L1 immunotherapy in GBM was the CheckMate 143 trial, which evaluated 369 patients with recurrent GBM who received either nivolumab (an anti-PD-1 monoclonal antibody) or bevacizumab [17].